• Completion of Phase 1 testing demonstrates 91% sensitivity and 85% specificity
• Further optimisation studies are currently being performed and are expected to continue to improve results and match WHO standards
• Next steps are completion of regulatory approvals and moving the technology to market as soon as possible

ZURICH, SWITZERLAND - EQS...